Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Non-Current Assets (2017 - 2025)

Eton Pharmaceuticals' Non-Current Assets history spans 8 years, with the latest figure at $31.5 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 10.17% to $31.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $131.3 million, a 142.72% increase, with the full-year FY2025 number at $31.5 million, down 10.17% from a year prior.
  • Non-Current Assets hit $31.5 million in Q4 2025 for Eton Pharmaceuticals, down from $32.5 million in the prior quarter.
  • Over the last five years, Non-Current Assets for ETON hit a ceiling of $35.1 million in Q4 2024 and a floor of $743000.0 in Q3 2021.
  • Historically, Non-Current Assets has averaged $11.4 million across 5 years, with a median of $5.0 million in 2022.
  • Biggest five-year swings in Non-Current Assets: plummeted 53.85% in 2021 and later soared 616.22% in 2024.
  • Tracing ETON's Non-Current Assets over 5 years: stood at $3.9 million in 2021, then surged by 30.17% to $5.0 million in 2022, then dropped by 2.49% to $4.9 million in 2023, then soared by 616.22% to $35.1 million in 2024, then dropped by 10.17% to $31.5 million in 2025.
  • Business Quant data shows Non-Current Assets for ETON at $31.5 million in Q4 2025, $32.5 million in Q3 2025, and $33.2 million in Q2 2025.